View Item 

Show simple item record

Impact of hospital guideline for weight‐based antimicrobial dosing in morbidly obese adults and comprehensive literature review
dc.contributor.authorPolso, A. K.en_US
dc.contributor.authorLassiter, J. L.en_US
dc.contributor.authorNagel, J. L.en_US
dc.date.accessioned2014-11-04T16:35:18Z
dc.date.availableWITHHELD_14_MONTHSen_US
dc.date.available2014-11-04T16:35:18Z
dc.date.issued2014-12en_US
dc.identifier.citationPolso, A. K.; Lassiter, J. L.; Nagel, J. L. (2014). "Impact of hospital guideline for weight‐based antimicrobial dosing in morbidly obese adults and comprehensive literature review." Journal of Clinical Pharmacy and Therapeutics 39(6): 584-608.en_US
dc.identifier.issn0269-4727en_US
dc.identifier.issn1365-2710en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109281
dc.publisherAPP Pharmaceuticals, LLCen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPharmacodynamicen_US
dc.subject.otherPharmacokineticen_US
dc.subject.otherObesityen_US
dc.subject.otherAntimicrobialsen_US
dc.subject.otherAntibioticsen_US
dc.titleImpact of hospital guideline for weight‐based antimicrobial dosing in morbidly obese adults and comprehensive literature reviewen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109281/1/jcpt12200.pdf
dc.identifier.doi10.1111/jcpt.12200en_US
dc.identifier.sourceJournal of Clinical Pharmacy and Therapeuticsen_US
dc.identifier.citedreferenceKoldin MH, Kobayashi GS, Brajtburg J, Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B‐induced toxicity in rabbits. Antimicrob Agents Chemother, 1985; 28: 144 – 145.en_US
dc.identifier.citedreferenceVadiei K, Lopez‐Berestein G, Luke DR. Disposition and toxicity of amphotericin‐B in the hyperlipidemic zucker rat model. Int J Obes, 1990; 14: 465 – 472.en_US
dc.identifier.citedreferenceGroll AH, Mickiene D, Piscitelli SC, Walsh TJ. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother, 2000; 44: 408 – 410.en_US
dc.identifier.citedreferenceRamaswamy M, Peteherych KD, Kennedy AL, Wasan KM. Amphotericin B lipid complex or amphotericin B multiple‐dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother, 2001; 45: 1184 – 1191.en_US
dc.identifier.citedreferenceGillum JG, Johnson M, Lavoie S, Venitz J. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy, 1995; 15: 251 – 253.en_US
dc.identifier.citedreferencePfizer Inc. ed. Vfend. New York, NY: Pfizer, Inc., 2011.en_US
dc.identifier.citedreferencePai MP, Lodise TP. Steady‐state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother, 2011; 55: 2601 – 2605.en_US
dc.identifier.citedreferenceKoselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother, 2012; 67: 2957 – 2962.en_US
dc.identifier.citedreferenceDavies‐Vorbrodt S, Ito JI, Tegtmeier BR, Dadwal SS, Kriengkauykiat J. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. Pharmacotherapy, 2013; 33: 22 – 30.en_US
dc.identifier.citedreferenceMoriyama B, Falade‐Nwulia O, Leung J et al. Prolonged half‐life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses, 2011; 54: e877 – e879.en_US
dc.identifier.citedreferenceMoriyama B, Jarosinski PF, Figg WD et al. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. Pharmacotherapy, 2013; 33: e19 – e22.en_US
dc.identifier.citedreferenceDickmeyer NJ, Kiel PJ. Dosing voriconazole in an obese patient. Clin Infect Dis, 2011; 53: 745.en_US
dc.identifier.citedreferenceBlum MR, Liao SHT, Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med, 1982; 73 ( Suppl 1A ): 186.en_US
dc.identifier.citedreferenceLaskin O. CLinical pharmacokinetics of acyclovir. Clin Pharmacokinet, 1983; 8: 187.en_US
dc.identifier.citedreferenceDavis R, Quenzer R, Weller S, Blum R. Acyclovir pharmacokinetics in morbid obesity. Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991.en_US
dc.identifier.citedreferenceHernandez JO, Norstrom J, Wysock G. Acyclovir‐induced renal failure in an obese patient. Am J Health Syst Pharm, 2009; 66: 1288 – 1291.en_US
dc.identifier.citedreferenceSeedat A, Winnett G. Acyclovir‐induced acute renal failure and the importance of an expanding waist line. BMJ Case Rep, 2012; 2012: 1 – 3.en_US
dc.identifier.citedreferenceZovirax (acyclovir sodium). Research Triangle Park, NC: GlaxoSmithKline, 2003.en_US
dc.identifier.citedreferenceVistide (cidofovir injection). Foster City, CA: Gilead Sciences, Inc., 2000.en_US
dc.identifier.citedreferenceFoscavir (foscarnet sodium). Wilmington, DE: AstraZeneca, 2012.en_US
dc.identifier.citedreferenceCytovene (ganciclovir sodium for injection). Nutley, NJ: Roche Laboratories, Inc., 2006.en_US
dc.identifier.citedreferenceOgden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief, 2012; 82: 1 – 8.en_US
dc.identifier.citedreferenceBauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol, 1983; 24: 643 – 647.en_US
dc.identifier.citedreferenceGuerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest, 2002; 122: 1256 – 1263.en_US
dc.identifier.citedreferenceMancuso P. Obesity and respiratory infections: does excess adiposity weigh down host defense? Pulm Pharmacol Ther, 2013; 26: 412 – 419.en_US
dc.identifier.citedreferenceFalagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis, 2006; 6: 438 – 446.en_US
dc.identifier.citedreferenceJain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther, 2011; 90: 77 – 89.en_US
dc.identifier.citedreferenceHanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet, 2010; 49: 71 – 87.en_US
dc.identifier.citedreferenceBenedek IH, Fiske WD III, Griffen WO, Bell RM, Blouin RA, McNamara PJ. Serum alpha 1‐acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol, 1983; 16: 751 – 754.en_US
dc.identifier.citedreferenceBrill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet, 2012; 51: 277 – 304.en_US
dc.identifier.citedreferenceAggarwal N, Porter AC, Tang IY, Becker BN, Akkina SK. Creatinine‐based estimations of kidney function are unreliable in obese kidney donors. J Transplant, 2012; 2012: 872894.en_US
dc.identifier.citedreferenceHites M, Taccone FS, Wolff F et al. Case–control study of drug monitoring of beta‐lactams in obese critically ill patients. Antimicrob Agents Chemother, 2013; 57: 708 – 715.en_US
dc.identifier.citedreferenceSchwartz SN, Pazin GJ, Lyon JA, Ho M, Pasculle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis, 1978; 138: 499 – 505.en_US
dc.identifier.citedreferenceBlouin RA, Mann HJ, Griffen WO Jr, Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther, 1979; 26: 508 – 512.en_US
dc.identifier.citedreferencePai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother, 2011; 55: 4006 – 4011.en_US
dc.identifier.citedreferenceKorsager S. Administration o gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol, 1980; 18: 549 – 553.en_US
dc.identifier.citedreferenceSketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol, 1981; 21: 288 – 293.en_US
dc.identifier.citedreferenceDuffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet, 2004; 43: 1167 – 1178.en_US
dc.identifier.citedreferenceBauer LA, Blouin RA, Griffen WO Jr, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm, 1980; 37: 519 – 522.en_US
dc.identifier.citedreferenceGibbs RS, Blanco JD, Lipscomb KA. Aminoglycoside dosing in obese puerperal women. Am J Obstet Gynecol, 1985; 152: 89 – 90.en_US
dc.identifier.citedreferenceBlouin RA, Brouwer KL, Record KE, Griffen WO Jr, Plezia PM, John W. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric‐bypass surgery. Clin Pharm, 1985; 4: 70 – 72.en_US
dc.identifier.citedreferenceOrtega A, Aldaz A, Giraldez J, Brugarolas A. Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. Pharm World Sci, 1999; 21: 227 – 232.en_US
dc.identifier.citedreferenceTobramycin. Schaumburg, IL: APP Pharmaceuticals, LLC, 2008.en_US
dc.identifier.citedreferencePogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin‐associated nephrotoxicity in a large academic health system. Clin Infect Dis, 2011; 53: 879 – 884.en_US
dc.identifier.citedreferenceDeryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother, 2010; 54: 4503 – 4505.en_US
dc.identifier.citedreferenceGauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother, 2012; 56: 2392 – 2396.en_US
dc.identifier.citedreferenceGaronzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother, 2011; 55: 3284 – 3294.en_US
dc.identifier.citedreferenceElwood CM, Lucas GD, Muehrcke RC. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med, 1966; 118: 326 – 334.en_US
dc.identifier.citedreferenceCubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals, Inc., 2013.en_US
dc.identifier.citedreferencePai MP, Norenberg JP, Anderson T et al. Influence of morbid obesity on the single‐dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother, 2007; 51: 2741 – 2747.en_US
dc.identifier.citedreferenceDvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol, 2005; 45: 48 – 56.en_US
dc.identifier.citedreferenceBubalo JS, Munar MY, Cherala G, Hayes‐Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother, 2009; 53: 428 – 434.en_US
dc.identifier.citedreferencePea F, Cojutti P, Sbrojavacca R et al. TDM‐guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother, 2011; 45: e37.en_US
dc.identifier.citedreferenceBhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis, 2010; 50: 1568 – 1574.en_US
dc.identifier.citedreferenceBookstaver PB, Bland CM, Qureshi ZP et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern united states. Pharmacotherapy, 2013; 33: 1322 – 1330.en_US
dc.identifier.citedreferenceNg J, Schulz L, Rose W et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother, 2014; 58: 88 – 93.en_US
dc.identifier.citedreferenceSynercid (quinupristin and dalfopristin). Greenville, NC: DSM Pharmaceuticals, Inc., 2012.en_US
dc.identifier.citedreferenceLefebvre P, Rey J, Morganroth J, Geary W, Montay G. Open, comparative, study of the safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500) in obese and in non‐obese male subjects. 20th International Congress of Chemotherapy, Sydney, Australia, 1997, Organising Committee, Vic., Australia.en_US
dc.identifier.citedreferenceBactrim (sulfamethoxazole and trimethoprim DS). Philadelphia, PA: AR Scientific, Inc., 2013.en_US
dc.identifier.citedreferenceGarrett ER, Suverkrup RS, Eberst K, Yost RL, O'Leary JP. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos, 1981; 2: 329.en_US
dc.identifier.citedreferenceBaxter Healthcare Corporation, ed. Vancomycin hydrochloride [package insert]. Deerfield, IL: Baxter Healthcare Corporation, 2011.en_US
dc.identifier.citedreferenceBauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol, 1998; 54: 621 – 625.en_US
dc.identifier.citedreferenceVance‐Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a bayesian forecasting technique. Antimicrob Agents Chemother, 1993; 37: 436 – 440.en_US
dc.identifier.citedreferencePenzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit, 1998; 20: 261 – 265.en_US
dc.identifier.citedreferenceBlouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother, 1982; 21: 575 – 580.en_US
dc.identifier.citedreferenceDucharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit, 1994; 16: 513 – 518.en_US
dc.identifier.citedreferenceLeong JV, Boro MS, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm, 2011; 68: 599 – 603.en_US
dc.identifier.citedreferenceReynolds DC, Waite LH, Alexander DP, DeRyke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm, 2012; 69: 944 – 950.en_US
dc.identifier.citedreferenceHeble DE Jr, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy, 2013; 33: 1273 – 1277.en_US
dc.identifier.citedreferenceAmBisome (amphotericin B). Northbrook, IL: Astellas Pharma US, Inc., 2012.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jcpt12200.pdf
Size:
600.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.